Northern Sexual Health, 8943Contraception and HIV Service, Manchester University NHS Foundation Trust, Manchester, UK.
Department of Haematology, 5293Manchester University NHS Foundation Trust, Manchester, UK.
Int J STD AIDS. 2021 Sep;32(10):978-980. doi: 10.1177/09564624211006568. Epub 2021 May 4.
Recurrence of mucocutaneous herpes simplex virus (HSV) infections is common in immunosuppressed patients. Thymidine kinase mutations conferring resistance to the antiviral agent aciclovir have been observed in such patients. Recommended second-line therapeutic agents against HSV are associated with significant side effects contributing to disease burden. We present a case of aciclovir-resistant herpes simplex virus 2 (HSV-2) in an immunosuppressed (HIV negative) allogenic peripheral blood stem cell transplant (SCT) recipient which was refractory to second-line therapy. Compassionate acquisition of the novel oral helicase-primase inhibitor pritelivir provided both symptomatic and virological control for the duration of its use. We believe this to be the first clinical use of this therapeutic agent in the United Kingdom.
复发性黏膜单纯疱疹病毒（HSV）感染在免疫抑制患者中很常见。在这些患者中，已经观察到具有抗抗病毒药物阿昔洛韦耐药性的胸苷激酶突变。针对 HSV 的推荐二线治疗药物与导致疾病负担的重大副作用有关。我们报告了一例免疫抑制（HIV 阴性）异基因外周血造血干细胞移植（SCT）受者中阿昔洛韦耐药性单纯疱疹病毒 2（HSV-2）的病例，该病例对二线治疗药物具有抗药性。新型口服解旋酶-引物抑制剂普立万的同情性获取为其使用期间的症状和病毒学控制提供了帮助。我们相信这是该治疗药物在英国的首次临床应用。
